We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Test Predicts Cancer Potential in Pancreatic Cysts

By LabMedica International staff writers
Posted on 01 Aug 2011
A gene-based test has been developed that distinguishes precancerous pancreatic cysts from benign vesicles by parallel sequencing. More...


Genetic analysis of precancerous fluid filled cysts and the search for mutations may eventually help more than a million patients each year avoid the possibility of needless surgery to remove the benign growths.

Scientists at Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) analyzed DNA from the cyst fluid of 19 intraductal papillary mucinous neoplasms and the corresponding normal tissue by massively parallel sequencing for mutations in 169 cancer genes. Fourteen of the 19 tumors showed mutations in the known pancreatic oncogene Kirsten rat sarcoma viral oncogene homolog (KRAS), and 6 of the 19 carried a mutation in the stimulatory G-protein alpha subunit (GNAS), a well-known oncogene in other tumor types.

Of a larger set of fluid samples from these cystic neoplasms, 96% carried a mutation in at least one of the two oncogenes. In contrast, 44 benign cysts exhibited no GNAS or KRAS mutations. KRAS mutations did appear occasionally in a rare type of cyst with a relatively low potential to become cancerous. According to the investigators, these rare, mostly benign cysts are less challenging to diagnose because of their location within the pancreas and type of patient.

Generally, patients with a cyst that appears harmless and is less than 3 cm in size are monitored to watch for growth of the cyst or other concerning features such as a solid nodule. With cysts that appear more worrisome, surgical removal is often recommended, but the procedure requires removal of a portion of the pancreas as well, and complications like a pancreatic fistula where fluid from the pancreas leaks through the surgical incision, eating difficulties, and prolonged recovery can develop.

Bert Vogelstein, MD, a lead author of the study, said, "Further studies on a larger number of patients must be done before the gene-based test can be widely offered. However, that the technology for developing a gene-based test in this case is relatively straightforward because the mutation occurs at one spot in both of the genes." The study was published the July 20, 2011, issue of Science Translational Medicine.

Related Links:
Johns Hopkins Kimmel Cancer Center




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.